dr. herzog on the optimal use of bevacizumab in patients with ovarian cancer
Published 6 years ago • 179 plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
3:13
dr. herzog on the fda approval of olaparib/bevacizumab as frontline maintenance in ovarian cancer
-
1:43
dr. herzog on the use of hipec in ovarian cancer
-
2:15
dr. herzog on impact of recent clinical trials in ovarian cancer
-
1:23
dr. herzog on novel therapies in ovarian cancer
-
1:45
dr. liu on the use of bevacizumab in newly diagnosed advanced ovarian cancer
-
1:08
dr. burger on the use of bevacizumab in ovarian cancer
-
23:15
is it time to change upfront chemotherapy for ovarian cancer?
-
7:48
hologic ceo steve macmillan on breast cancer detection, future of ai-powered diagnostics
-
7:24
ovarian cancer: maintenance following frontline bevacizumab
-
8:15
bevacizumab in ovarian cancer
-
1:19
real-world use of bevacizumab in patients with breast cancer
-
2:56
patient selection for bevacizumab in ovarian cancer
-
1:40
dr. hardesty on bevacizumab/parp inhibitor combination in ovarian cancer
-
7:32
bevacizumab for recurrent ovarian cancer
-
1:06
dr. jason konner discusses bevacizumab in ovarian cancer
-
1:40
dr. burger on the toxicity profile of bevacizumab in ovarian cancer
-
1:00
dr. kris on the impact of bevacizumab biosimilars in lung cancer
-
1:59
dr. gilbert on the safety profile of mirvetuximab soravtansine/bevacizumab in ovarian cancer
-
6:04
when to add bevacizumab for recurrent ovarian cancer